Belite Bio, Inc (BLTE) Stock Score, Valuation & Financial Research

Belite Bio, Inc is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for BLTE

Belite Bio, Inc does not currently have a complete Wall Street Score. The stored market price is USD 169.82. These figures are a research snapshot, not a buy or sell recommendation.

What Belite Bio, Inc does

Belite Bio, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and advancement of novel therapies. The firm's primary therapeutic areas include atrophic age-related macular degeneration and autosomal recessive Stargardt disease. Its flagship drug candidate, LBS-008, is an investigational oral medication administered once daily. Currently undergoing Phase 3 clinical trials, LBS-008 is engineered to modulate vitamin A delivery to the eye, thus preventing the accumulation of detrimental vitamin A metabolites in ocular tissues. Furthermore, Belite Bio is advancing LBS-009, an oral anti-retinol binding protein 4 therapy, through preclinical development. This therapy targets various liver ailments, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes. Founded in 2016, Belite Bio, Inc. is headquartered in San Diego, California, and operates as a subsidiary of Lin Bioscience International Ltd.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

Belite Bio is a clinical-stage biopharmaceutical company that does not currently generate revenue from product sales. Its business model focuses on the research and development of novel therapeutics for degenerative retinal diseases and metabolic disorders, relying on capital raises and financing to fund its ongoing clinical trials and operations.

Products and services

  • The company's lead product candidate is Tinlarebant, an oral therapy for Stargardt disease type 1 and geographic atrophy in advanced dry age-related macular degeneration. It also has a preclinical candidate, LBS-009, for metabolic diseases.

Suppliers, materials and equipment

  • Contract Research Organizations (CROs) — The company enters into cancelable contracts with various unnamed CROs for clinical trials, preclinical studies, and manufacturing services. Source

Business relationships and partnerships

  • Columbia University — The company holds an exclusive worldwide license to an RBP4 intellectual property portfolio from Columbia University for the development of its therapeutic candidates. Source

Business strengths to evaluate

  • Exclusive worldwide license to RBP4 intellectual property portfolio Source

Business risks and research considerations

  • Clinical trial delays or termination Source
  • Regulatory compliance and pharmacovigilance obligations Source

Sources: Company research source

Company research refreshed 2026-10-12. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

BLTE financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 169.82
Market capitalization:
6.81B (currency not supplied)
Revenue:
USD 0.00
Net income:
USD -102.36M
Free cash flow:
USD -37.17M
Cash:
USD 352.93M
Total debt:
USD 429K
EPS:
USD -2.76

What stands out

  • Free cash flow is USD -37.17M, negative for the stored period.
  • The balance sheet shows USD 352.93M of cash versus USD 429K of total debt, an excess of cash over debt on these two reported measures.
  • The current research record carries a fundamental change risk warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Cash exceeds debt by USD 352.5M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for BLTE

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • How long can BLTE fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • How is BLTE likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
  • What specifically needs to improve for BLTE to reach sustainable profitability?
  • What does the current fundamental change risk warning mean for the reliability or interpretation of BLTE's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-01.

Research-input completeness: 73% of the scoring inputs required for this public page are currently available.

How to research BLTE

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.